Literature DB >> 3609177

Persistence of rabies antibody 5 years after pre-exposure prophylaxis with human diploid cell antirabies vaccine and antibody response to a single booster dose.

F M Rodrigues, V B Mandke, M Roumiantzeff, C V Rao, J M Mehta, K M Pavri, C Poonawalla.   

Abstract

In 1978, 22 staff members of the National Institute of Virology, Pune, India, were given two doses of human diploid cell antirabies vaccine (HDCV) for primary pre-exposure prophylactic immunization; the interval between the two doses being approximately 4 weeks. Eighteen of these 22 vaccinees were given a booster dose 1 year later. All 18 vaccinees developed protective levels of antibody; most of them had antibody levels exceeding 10 IU/ml. In 1984, 5 years after the booster dose, 11 (79.0%) of 14 vaccinees tested still possessed neutralizing antibody levels ranging from 0.5 IU/ml to 10 IU/ml. Fourteen days after the administration of a booster dose, the antibody levels ranged from 10 to greater than or equal to 100 IU/ml for all except one vaccine (5.2 IU/ml). These findings demonstrate that the majority of vaccines retained detectable neutralizing antibody after pre-exposure prophylaxis for as long as 5 years and that a single booster dose thereafter evoked a good antibody response.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3609177      PMCID: PMC2249170          DOI: 10.1017/s0950268800066899

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  7 in total

1.  A rapid reproducible test for determining rabies neutralizing antibody.

Authors:  J S Smith; P A Yager; G M Baer
Journal:  Bull World Health Organ       Date:  1973-05       Impact factor: 9.408

2.  Successful protection of humans exposed to rabies infection. Postexposure treatment with the new human diploid cell rabies vaccine and antirabies serum.

Authors:  M Bahmanyar; A Fayaz; S Nour-Salehi; M Mohammadi; H Koprowski
Journal:  JAMA       Date:  1976-12-13       Impact factor: 56.272

3.  Immunogenicity and acceptability of a human diploid-cell culture rabies vaccine in volunteers.

Authors:  F Y Aoki; D A Tyrrell; L E Hill
Journal:  Lancet       Date:  1975-03-22       Impact factor: 79.321

4.  Rabies prevention--United States, 1984.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1984-07-20       Impact factor: 17.586

5.  Immunization with a human diploid cell strain of rabies virus vaccine: two-year results.

Authors:  K G Nicholson; G S Turner; F Y Aoki
Journal:  J Infect Dis       Date:  1978-06       Impact factor: 5.226

6.  Booster effect of human diploid cell antirabies vaccine in previously treated persons.

Authors:  A Fayaz; S Simani; S Nour-Salehi; M Bahmanyar
Journal:  JAMA       Date:  1981-11-20       Impact factor: 56.272

Review 7.  Rabies vaccine prepared in human cell cultures: progress and perspectives.

Authors:  S A Plotkin
Journal:  Rev Infect Dis       Date:  1980 May-Jun
  7 in total
  1 in total

1.  Vaccination with rabies to study the humoral and cellular immune response to a T-cell dependent neoantigen in man.

Authors:  D M C Brinkman; C M Jol-van der Zijde; M M ten Dam; J M Vossen; A D M E Osterhaus; F P Kroon; M J D van Tol
Journal:  J Clin Immunol       Date:  2003-11       Impact factor: 8.542

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.